Corient Private Wealth LLC Sells 283,195 Shares of Zoetis Inc. $ZTS

Corient Private Wealth LLC lessened its stake in Zoetis Inc. (NYSE:ZTS) by 27.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 760,732 shares of the company’s stock after selling 283,195 shares during the period. Corient Private Wealth LLC’s holdings in Zoetis were worth $95,841,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. J. Stern & Co. LLP raised its holdings in Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after purchasing an additional 23,877,416 shares in the last quarter. Norges Bank bought a new stake in shares of Zoetis in the 4th quarter valued at about $734,425,000. Vanguard Group Inc. boosted its holdings in shares of Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after buying an additional 5,474,210 shares in the last quarter. Nordea Investment Management AB grew its position in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after buying an additional 2,179,578 shares during the last quarter. Finally, Van ECK Associates Corp raised its stake in shares of Zoetis by 269.0% during the 4th quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock worth $300,340,000 after acquiring an additional 1,740,113 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, The Gross Law Firm, Kessler Topaz, Bragar Eagel & Squire, and others, announced or reiterated securities class actions against Zoetis, with claims tied to alleged misstatements and omissions about product adoption during the January 14, 2025 to May 6, 2026 period. Article Title
• Negative Sentiment: The lawsuits highlighted a July 27, 2026 lead-plaintiff deadline and suggested investors who bought ZTS during the class period may have suffered losses, increasing legal overhang and uncertainty for the stock. Article Title
• Neutral Sentiment: Zacks noted ZTS recently outperformed the broader market, but that commentary was largely backward-looking and did not change the heavier focus on litigation headlines. Article Title

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Stifel Nicolaus decreased their target price on shares of Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a research report on Friday, May 22nd. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Morgan Stanley reissued an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a research report on Friday, May 15th. Finally, BTIG Research restated a “buy” rating and set a $160.00 target price on shares of Zoetis in a research note on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and an average target price of $133.92.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Paul Bisaro acquired 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares of the company’s stock, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Frank A. Damelio bought 6,650 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the acquisition, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis Stock Down 0.0%

Shares of ZTS stock opened at $78.69 on Friday. The stock’s 50-day simple moving average is $93.01 and its 200-day simple moving average is $112.54. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The firm has a market capitalization of $32.99 billion, a PE ratio of 13.05, a P/E/G ratio of 1.23 and a beta of 0.75. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $161.77.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.